Study of Recombinant Human GM-CSF in Cancer Patients
Author Information
Author(s): W.P. Steward, J.H. Scarffel, R. Austin, E. Bonnem, N. Thatcher, G. Morgenstern, D. Crowther
Primary Institution: Christie Hospital, Manchester, UK
Hypothesis
Does recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) increase white blood cell counts and reduce toxicity in patients with metastatic solid tumors?
Conclusion
The study found that rhGM-CSF significantly increased white blood cell counts but also caused notable toxicity at higher doses.
Supporting Evidence
- Significant increases in total leucocyte, neutrophil, and eosinophil counts were observed at doses of 10 µg/kg and above.
- 80% of patients experienced severe toxicity at the maximum tolerated dose of 60 µg/kg.
- Seven patients experienced stabilization of their disease while receiving GM-CSF.
- One patient had a greater than 50% reduction in tumor volume after treatment.
Takeaway
This study tested a medicine that helps the body make more white blood cells in cancer patients, and it worked but also caused some side effects.
Methodology
Patients received daily intravenous infusions of rhGM-CSF over three phases with escalating doses to evaluate effects and toxicity.
Limitations
Only a small number of patients completed the study at the highest dose due to severe toxicity.
Participant Demographics
All participants had advanced solid tumors and were over 18 years old.
Statistical Information
P-Value
p<0.005 for total leucocyte count
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website